#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Pleural mesothelioma malignant Paraneoplastic neurological syndrome Deafness bilateral Oesophageal adenocarcinoma Renal cell carcinoma Vulval cancer Rhabdomyosarcoma recurrent Aicardi-Goutieres syndrome Graft versus host disease Chondrosarcoma Brain abscess Oropharyngeal squamous cell carcinoma Sarcoidosis Keratosis follicular Eosinophilic oesophagitis More trials…

    Learn about Rare Diseases

    Synovial sarcoma metastatic – Treatment Pulmonary sarcoidosis – Diagnostics Rhabdoid tumour – Trials in Disease Primary mediastinal large B-cell lymphoma – Treatment Mantle cell lymphoma stage III – Treatment Cystic fibrosis lung – Treatment Ewing’s sarcoma metastatic – Treatment Ornithine transcarbamoylase deficiency – Basic Information Prader-Willi syndrome Hereditary hypophosphataemic rickets – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Losartan Potassium Vusolimogene Oderparepvec Ioflupane (123I) Tanimilast Etamsylate Isoflurane Permethrin AMODIAQUINE ZOREVUNERSEN SODIUM Immunostimulants Lactose Xaluritamig R2R01 Bezafibrate Sodium Nitroprusside Dihydrate Mesalazine Esketamine Erdafitinib Bjt-778 Bevacizumab More therapies…

    Learn about Your Condition

    Pleomorphic liposarcoma Graft versus host disease Shock Polycystic liver disease Transferrin decreased Nodal osteoarthritis Stem cell transplant Cytokine release syndrome Acute leukaemia Colorectal cancer stage III Actinic keratosis Pleural mesothelioma malignant Rectosigmoid cancer PIK3CA-activated mutation Skin neoplasm excision More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Non-small cell lung cancer

  • Study on the Safety and Tolerability of TUB-040 for Patients with Platinum-Resistant Ovarian Cancer or Relapsed/Refractory Non-Small Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    • Adenocarcinoma
    • Ovarian cancer
    • Non-small cell lung cancer
    Investigated Drugs:
    • Tub-040
    Belgium Germany Romania Spain

  • Study of Sacituzumab and Zimberelimab for Patients with Resectable Non-Small Cell Lung Cancer After Surgery Without Complete Disease Clearance

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Zimberelimab
    Spain

  • Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of lung
    • Non-small cell lung cancer
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • D-Ala-Lys-Cha-Val-Ala-Ala-Trp-Thr-Leu-Lys-Ala-Ala-D-Ala
    • Mps-102
    • Mps-103
    Belgium France Germany Greece Hungary Italy +5

  • Study of Pembrolizumab and Lenvatinib for Patients with Resectable Non-Small-Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Lenvatinib
    • Pembrolizumab
    Austria

  • Study of Pembrolizumab, Vibostolimab, and Chemotherapy for Patients with Newly Diagnosed Resectable Stage II-IIIB Non-Small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Sacituzumab Tirumotecan
    • Pemetrexed Disodium
    • Buclizine Hydrochloride
    Germany Greece Hungary Italy Poland Spain

  • Study of Durvalumab, Tremelimumab, Chemotherapy, and Radiotherapy for Patients with Newly Diagnosed Non-Small Cell Lung Cancer with Limited Spread

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Tremelimumab
    • Durvalumab
    Italy The Netherlands Spain
Previous Page
1 … 9 10 11 12 13 … 54
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!